Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Korea
Biotech
GemVax's peptide drug fails phase 2a neurodegenerative trial
Korea's GemVax revealed that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy.
Fraiser Kansteiner
Oct 29, 2024 11:28am
Readying for next pandemic, Korea's SK pumps $261M into R&D site
Feb 8, 2023 9:40am
Boston Scientific offers $230M for Korean stent maker
Jun 15, 2022 12:15pm
Bioasis, Neuramedy sign blood-brain barrier pact for $72M
May 11, 2022 10:55am
Bavarian Nordic sells China rights to RSV vaccine in $225M deal
Mar 21, 2022 9:25am
D&D Pharma nabs $51M before Korean IPO for Alzheimer's
Oct 19, 2021 7:00am
